^
Association details:
| Biomarker: | SF3B1 K666N |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | spliceostatin A (SSA) (SF3B1 inhibitor, RNA splicing modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SF3B1 mutations constitute a novel therapeutic target in breast cancer
Excerpt:
Treatment of two SF3B1 mutant cell lines, Panc 05.04 (pancreatic, K700E) and ESS-1 (endometrial, K666N), and six wild-type controls (three pancreatic and three endometrial) with an SF3b complex inhibitor, spliceostatin A, revealed that SF3B1 mutant cell lines were significantly more sensitive to this agent (p = 0.0118, t-test, Figure 3A).
DOI:
10.1002/path.4483
